
5M Biomed LLC Profile last edited on: 8/10/2021
CAGE: 8DVT9
UEI: K82GCNF5EPU3
Business Identifier: Enabling precision medicine Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 06
County: Fulton
Congr. District: 06
County: Fulton
Public Profile
A high-tech startup company founded by a group of biomedical researchers, engineers and clinical scientists specializing in life sciences, diagnostics and technology development in biomaterials, medical imaging and imaging informatics, 5M Biomed, LLC is a part of fast-growing biotechnology industrial and academic communities in the state of Georgia, Organized around enabling precision medicine in molecular and biomarker specific medical imaging, in vitro diagnostics and drug delivery, the firm is ridging the gap between the demand and supply of magnetic nanomaterials, 5M' research supports the product development with the latest and advanced nanomaterial fabrication. and also offers services in nanomaterial characterization and analysis, in vitro and in vivo assay development and data analysis.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 1 | NIH | $306,433 | |
Project Title: Multi-functional magnetic nanorods for constructing theranostic extracellular vesicles for treating myocardial infarction | ||||
2022 | 1 | NIH | $399,840 | |
Project Title: Highly Sensitive and Robust Blood Test Platform for Screening and Early Detection of Alzheimer's Disease | ||||
2021 | 1 | NIH | $299,931 | |
Project Title: Small Intestine Targeted Fast Acting Oral Insulin Formulation | ||||
2021 | 1 | NIH | $400,000 | |
Project Title: A New Class of Magnetic Nanoparticles for Glioma Targeted Drug Delivery | ||||
2020 | 1 | NIH | $319,726 | |
Project Title: Serum Detection of Medulloblastoma Metastasis |
Key People / Management
Mao Hui
Yuancheng Li -- Vice President & Chief Scientific Officer
Yuancheng Li -- Vice President & Chief Scientific Officer
Company News
There are no news available.